In one of the largest licensing deals in the Australian biotechnology industry, Dimerix (ASX:DXB) has signed an exclusive US licence agreement with Amicus Therapeutics to commercialise its kidney disease drug candidate DMX-200. …
Dimerix secures one of the largest licensing deals in Australian biotechnology
May 1, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
Arthritis Australia appoints Louise Hardy as CEO at pivotal moment for national advocacy
February 2, 2026 - - Latest News -
AusBiotech urges adoption of national life sciences strategy as global competition intensifies
February 2, 2026 - - Australian Biotech -
Cyclopharm delivers record revenue as US emerges as growth engine
February 2, 2026 - - Australian Biotech -
Sandoz adds to vision care options with the listing of biosimilar
February 2, 2026 - - Latest News -
PYC’s capital raise marks one of the largest biotech fundraisings in Australian market history
February 2, 2026 - - Australian Biotech -
Genetic Signatures appoints seasoned life sciences executive as CEO
February 2, 2026 - - Australian Biotech -
EMA decision clears regulatory path for Argenica’s lead stroke drug in Europe
February 2, 2026 - - Australian Biotech